Budget impact model suggests adding rucaparib to the formulary for US health plans for patients with metastatic ovarian cancer adds negligible costs in all tested settings and scenarios (Pharmacoeconomics. 2020. doi:10.1007/s40273-020-00970-y).
“A budget impact model was constructed to assess the incremental budget impact that rucaparib availability would have on a US health plan,” wrote the study authors.
Over a 3-year horizon, an incremental budget impact was estimated. The difference in total annual cost of treatment with and without rucaparib available, for second-line maintenance, third-line treatment, and the combined maintenance and treatment settings was estimated in the budget.
The hypothetical health plan included 1,000,000 covered lives, and the eligible patient population was estimated using an incidence-based approach. Costs including drug acquisition, intravenous drug administration, required laboratory testing, and medical management of adverse events were modeled in the plan.
Total costs over 3 years with rucaparib were $1,465,043 versus $1,461,350 without it as a treatment, with a PMPM impact of $0.0003 in the maintenance setting. In the treatment setting, PMPM costs were $0.0006.
“The budget impact of adding rucaparib to the formulary for a health plan adds negligible PMPM costs of <$0.001 in all tested settings and scenarios due to the small population eligible for therapy,” concluded the study authors.—Lisa Kuhns
